Merck & Co Inc’s (MRK) patritumab deruxtecan demonstrated statistically significant improvement in progression-free survival compared to standard chemotherapy in a Phase 3 trial for EGFR-mutated non-small cell lung cancer (NSCLC). This positive outcome comes as Summit Therapeutics Inc’s (SMMT) ivonescimab also showed promising results against Merck’s Keytruda (pembrolizumab) in a separate lung cancer trial.
Johnson & Johnson’s Rybrevant, a lung cancer treatment, continues to demonstrate positive results. A new study shows that a prophylactic strategy significantly reduces infusion-related reactions, while long-term data from the MARIPOSA study reinforces Rybrevant’s effectiveness in combination with Lazcluze, improving survival and disease control compared to standard treatment.
Summit Therapeutics’ ivonescimab demonstrated a significant improvement in progression-free survival compared to Keytruda in a Phase 3 trial for non-small cell lung cancer. The drug also showed positive results in a Phase 2 trial for resectable lung cancer, highlighting its potential as a promising treatment option.
Merck & Co Inc has discontinued two Phase 3 trials evaluating Keytruda (pembrolizumab) for the treatment of non-small cell lung cancer and cutaneous squamous cell carcinoma. The decision was based on recommendations from independent Data Monitoring Committees, which found that Keytruda did not demonstrate a statistically significant improvement in survival or recurrence-free survival compared to placebo.
The FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy for adult patients with resectable early-stage non-small cell lung cancer (NSCLC) who do not have certain genetic mutations. This approval is based on positive results from the AEGEAN trial, demonstrating a significant reduction in the risk of recurrence and improved pathological complete response rates. Imfinzi is also being evaluated for use in limited-stage small cell lung cancer.
Susan Wojcicki, a prominent figure in the tech industry and former CEO of YouTube, has passed away at the age of 53 after a two-year fight against non-small cell lung cancer. Her husband, Dennis Troper, shared the news on Facebook, expressing his deep sorrow and love for his late wife.
World Lung Cancer Day, observed annually on August 1st, highlights the importance of raising awareness about this deadly disease, its symptoms, and crucial prevention strategies. This article delves into the various aspects of lung cancer, including its types, symptoms, treatment options, and the role of early detection, genetic factors, and lifestyle modifications in mitigating risk. It also explores the latest advancements in research and treatment approaches, as well as the importance of emotional support for patients and their families.
Lung cancer, a leading cause of death globally, is increasingly affecting non-smokers in Southeast Asia, particularly India. This alarming trend is attributed to a combination of factors including air pollution, genetic predisposition, and delayed diagnosis due to high tuberculosis rates. The study highlights the unique challenges faced by the region, emphasizing the need for early detection, improved access to treatment, and awareness about the multifaceted nature of the disease.
At 56, Calgary’s renowned golfer Steve Blake received a life-altering diagnosis of Stage 4 lung cancer. Despite the prognosis of 12 to 24 months, Blake’s unwavering belief and support system have driven him to embrace life and continue playing the game he loves. With a sponsor exemption, he will participate in this year’s Rogers Charity Classic, demonstrating his resilience and inspiring others facing similar challenges.
Lung cancer and asthma share some symptoms, such as coughing and shortness of breath. However, these conditions have distinct characteristics that can help differentiate them. Lung cancer, a leading cause of cancer-related deaths worldwide, often presents with chest pain, coughing up blood, and fatigue. Asthma, a chronic respiratory condition, is characterized by wheezing, triggered by specific irritants or allergies. Age, trigger factors, and non-resolving symptoms can also provide clues in distinguishing between the two conditions.
